Core Viewpoint - The announcement highlights the long-term efficacy and safety of pimicotinib in treating TGCT patients, as presented at the CTOS 2025 conference, reinforcing its potential for long-term application in suitable patients [1] Group 1: Company Information - Shanghai Heyu Biopharmaceutical Technology Co., Ltd., a subsidiary of Heyu-B, showcased data from the global Phase III MANEUVER study on pimicotinib for TGCT patients [1] - The study results indicate that continuous treatment with pimicotinib leads to sustained improvements in tumor response and patient-reported outcomes, including pain and function [1] Group 2: Industry Insights - The findings from the MANEUVER study strengthen the position of pimicotinib in the treatment landscape for TGCT, suggesting a viable long-term treatment option for patients [1] - The acceptable safety profile maintained during the study supports the ongoing development and potential market introduction of pimicotinib for this indication [1]
和誉-B(02256)：和誉医药于CTOS 2025年会展示匹米替尼临床III期 MANEUVER研究长期疗效和安全性数据